Toronto, ON -- (SBWIRE) -- 05/02/2016 -- ChroMedX Corp. (the "Company"), a developer of in vitro diagnostics and point-of-care testing (POCT) is pleased to report on the Company's HemoPalm development program.

During the first four months of 2016, ChroMedX focused on refining the HemoPalm cartridge design through machining, and developing essential components of the HemoPalm analyzer.

"We have made significant progress so far in 2016 and are very pleased that there have been several important developments which will expand the utility and market of the HemoPalm. We have successfully engaged new technical resources and have concentrated efforts on our cartridge and biosensor technologies. The Company is now focused on optimizing the cartridge development in order to shift to the process of molding, and completion of the breadboard analyzer for testing the cartridges." said Dr. Wayne Maddever, President & CEO. "

HemoPalm Development

The HemoPalm project has made progress on several key fronts. The HemoPalm system consists of a disposable single use cartridge and a handheld analyzer. The system utilizes both spectroscopic measurements for CO-oximetry and bilirubin, and biosensor measurements for blood gases and electrolytes.

Proof-of-concept for CO-oximetry and bilirubin was completed. CO-oximetry is the gold standard for hemoglobin and oxygen saturation measurements and the inclusion of this technology makes the HemoPalm the only hand held analyzer in the world to combine COoximetry, blood gases and electrolytes. In addition, the successful demonstration of the measurement of bilirubin, an indicator of liver function and essential for the detection of neonatal jaundice, will expand the market for the HemoPalm.

The other critical development area is that of the electrochemical sensors used in the cartridge. ChroMedX recently announced the addition of Conductive Technologies Inc. (CTI) of York, PA. to this effort that is led by Polygenesis. CTI, which produced the current gold sensor array on a polymer substrate brings over 60 years of sensor and electronics expertise to the project and is leading the development of automated deposition of the critical ion selective membranes to the sensor array. Polygenesis has a long history in the field and the principal was part of the development team that created the Abbott i-Stat analyzer.

The Company previously reported on the cartridge development work being undertaken with Shenzhen Hochuen Technologies Co. Ltd. of Shenzhen China. Led by Dr. James Samsoondar, ChroMedX CSO, the cartridge has undergone several iterations of design refinement and recently demonstrated blood flow into the optical chamber by capillary action, for subsequent spectroscopic analysis. Design of the microfluidics is a critical aspect of the cartridge design and is patent protected. Another patent protected aspect of the cartridge design will allow for sample collection from a simple finger prick, or heel prick in the case of neonates, directly into the cartridge without the need for collection with a capillary tube and subsequent transfer. This aspect of the HemoPalm cartridge is not available in any hand-held or lab blood gas analyzer.

After successfully testing cartridges on the breadboard analyzer as mentioned before, the next step would be to package the analyzer components into a hand-held analyzer, and proceed towards clinical testing of the HemoPalm system for FDA submission.

About ChroMedX Corp.
ChroMedX Corp. is a medical technology company focused on the development of novel medical devices for in vitro diagnostics and point-of-care testing. The devices are protected by the Company's issued and pending patents, dealing with blood collection, analysis and plasma/serum processing.

Follow ChroMedX Corp.:
Facebook: http://facebook.com/ChroMedXcorp
Twitter: http://www.twitter.com/ChroMedXcorp

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Forward-looking Information Cautionary Statement

Except for statements of historic fact, this news release contains certain "forward-looking information" within the meaning of applicable securities law. Forward-looking information is frequently characterized by words such as "plan", "expect", "project", "intend", "believe", "anticipate", "estimate" and other similar words, or statements that certain events or conditions "may" or "will" occur. Forward-looking statements are based on the opinions and estimates at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking statements including, but not limited to delays or uncertainties with regulatory approvals, including that of the CSE. There are uncertainties inherent in forward-looking information, including factors beyond the Company's control. The Company undertakes no obligation to update forward-looking information if circumstances or management's estimates or opinions should change except as required by law. The reader is cautioned not to place undue reliance on forward-looking statements. Additional information identifying risks and uncertainties that could affect financial results is contained in the Company's filings with Canadian securities regulators, which filings are available at http://www.sedar.com.

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

Toronto, ON -- (SBWIRE) -- 12/15/2015 -- ChroMedX Corp.(the "Company"), a developer of in vitro diagnostics and point-of-care testing (POCT) devices is pleased to report the development of a proof-of-concept prototype of the Company's HemoPalm(TM) analyzer and associated cartridge for measuring CO-oximetry and bilirubin*.

The prototype analyzer uses the same light source and spectrophotometer that will be used in the final HemoPalm(TM) analyzer, and the prototype cartridge is consistent with the optical chamber of the final HemoPalm(TM) cartridge.

"The completion of this prototype is a significant milestone in the process of integrating CO-oximetry, blood gases and electrolytes in a single disposable cartridge. Comparison of results from testing of the HemoPalm(TM) spectrophotometer component with results from an FDA approved benchtop analyzer (IL GEM4000) has demonstrated equivalence between the two analyzers," said Dr. Wayne Maddever, President & CEO, ChroMedX Corp. "The addition of CO-oximetry to blood gases and electrolyte testing represents a significant competitive advantage over existing products in the marketplace and a separate cartridge for measuring neonatal bilirubin is expected to provide even greater market penetration," he added.

ChroMedX is positioned to be the first company to integrate blood gases, electrolytes and CO-oximetry in one hand-held analyzer and holds important patent protection. Up until the early 1990s, laboratory blood gas analyzers and CO-oximeters were separate analyzers. Currently, laboratory blood gas analyzers and CO-oximeters are integrated, but only as benchtop or cart configurations. The majority of this market is held by hand-held analyzers that do not provide CO-oximetry, and by analyzers that do provide CO-oximetry but must be wheeled on carts due to size.

The blood gas and electrolyte market is expected to be valued at approximately $1 Billion (US) by 2019 (Frost & Sullivan 2013).

* CO-oximetry is the gold standard for measuring different hemoglobin (Hb) species in blood (Total-Hb, Oxy-Hb, Deoxy-Hb, Met-Hb and Carboxy-Hb), and Hb-oxygen saturation by technology referred to as spectrophotometry. Bilirubin is an important test for monitoring liver function, and is also essential for detecting neonatal jaundice.

About ChroMedX Corp.
ChroMedX Corp. is a medical technology company focused on the development of novel medical devices for in vitro diagnostics and point-of-care testing. The devices are protected by the Company's issued and pending patents, dealing with blood collection, analysis and plasma/serum processing.

Follow ChroMedX Corp.:
Facebook: facebook.com/ChroMedXcorp
Twitter: http://www.twitter.com/ChroMedXcorp

Investor Relations:
Shawn Overton
d. 647-528-9344
o. 647-872-9982 ext. 2
TF. 844-247-6633 ext. 2
soverton@ChroMedX.com

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Forward-looking Information Cautionary Statement
Except for statements of historic fact, this news release contains certain "forward-looking information" within the meaning of applicable securities law. Forward-looking information is frequently characterized by words such as "plan", "expect", "project", "intend", "believe", "anticipate", "estimate" and other similar words, or statements that certain events or conditions "may" or "will" occur. Forward-looking statements are based on the opinions and estimates at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking statements including, but not limited to delays or uncertainties with regulatory approvals, including that of the CSE. There are uncertainties inherent in forward-looking information, including factors beyond the Company's control. The Company undertakes no obligation to update forward-looking information if circumstances or management's estimates or opinions should change except as required by law. The reader is cautioned not to place undue reliance on forward-looking statements.

Additional information identifying risks and uncertainties that could affect financial results is contained in the Company's filings with Canadian securities regulators, which filings are available at http://www.sedar.com.

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

Toronto, ON -- (SBWIRE) -- 12/10/2015 -- ChroMedX Corp. (the "Company"), a developer of in vitro diagnostics and point-of-care testing (POCT) is pleased to report that it has engaged Hochuen International Corp. to produce an enhanced version of its prototype HemoPalm cartridges.

ChroMedX Corp. has entered into a development agreement with Hochuen International Corp. to produce the enhanced version of its HemoPalm cartridges by machining as a preliminary step, which will be followed by injection molding.

"By utilizing the knowledge gained from micro-machined cartridges conducted at McMaster university, the Company has made significant improvements to the cartridge design and can now move to the important step of manufacture of HemoPalm cartridges by injection moulding," said Dr. Wayne Maddever, President & CEO, ChroMedX Corp.

ChroMedX previously announced its development program with McMaster University's Manufacturing Research Institute (MMRI), when fabrication of a prototype HemoPalm cartridge, a key component of the HemoPalm analysis system, was completed. As a result of the McMaster work, the Company has developed an improved cartridge which is smaller and will reduce manufacturing costs.

Other Business
The Company has granted an additional 620,000 stock options to certain directors and consultants pursuant to the Company employee stock option plan. The options are exercisable at $0.20 for a term of 5 years and vest over a 3-year term.

About Hochuen
Hochuen was founded in 2000 with specialization in die cutting, printing, CNC, plastic injection molding and assembly. The company is located in Shenzhen, China with over 3,500 employees. There are 3 manufacturing plants with total 800,000 square feet, including a class 10,000 clean room for medical device manufacturing. In 2012, Hochuen opened US office in Los Angeles.

In 2012, Hochuen was certified with ISO13485, and has served the biomedical and life science community with high quality biological testing and diagnostics consumables and device components. Hochuen attracts world class talents with microfluidics and medical devices experience. It also serves as a microfluidics design house with the following design capabilities: micro mixing, micro valves, micro pumps and integrated devices.

About ChroMedX Corp.
ChroMedX Corp. is a medical technology company focused on the development of novel medical devices for in vitro diagnostics and point-of-care testing. The devices are protected by the Company's issued and pending patents, dealing with blood collection, analysis and plasma/serum processing.

Follow ChroMedX Corp.:
Facebook: http://www.facebook.com/ChroMedXcorp
Twitter: http://www.twitter.com/ChroMedXcorp

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

Toronto, ON -- (SBWIRE) -- 10/15/2015 -- ChroMedX Corp. (the "Company"), a developer of in vitro diagnostics and point-of-care testing (POCT) is pleased to announce that the Company has been awarded a United States patent on its Ultra Filtration technology.

ChroMedX was awarded US Pat. No. 9,162,186, entitled "Sample Filtration Assembly". This patent is related to manual ultrafiltration cartridges, and while related to two recently announced Canadian patents on the Company's Automated Ultrafiltration (AUF) system, presents a new business opportunity for ChroMedX.

One potential application of the technology claimed in US 9,162,186 is to extract plasma from blood during the time blood is drawn from a patient. Usually blood is drawn into a vacuum filled tube, and the plasma is extracted in a central laboratory by centrifuging the tube of blood. By providing plasma separation immediately at the time of sampling, this technology provides a means for POCT that cannot be performed accurately on whole blood. A second claimed application is to provide disposable manual plasma ultrafiltration cartridges for measuring unbound drugs and hormones (i.e. biologically active drugs and hormones), to laboratories that cannot afford an AUF workstation.

This patent further demonstrates the novelty and usefulness of the Company's ultrafiltration technology and provides ChroMedX with new business opportunities in addition to its HemoPalmTM and AUF technologies.

This patent is a part of the Company's suite of issued and pending patents covering all of its technologies. A complete list of the Company's intellectual property can be found on the ChroMedX website at http://www.chromedx.com

About ChroMedX Corp.
ChroMedX Corp. is a medical technology company focused on the development of novel medical devices for in vitro diagnostics and point-of-care testing. The devices are protected by the Company's issued and pending patents, dealing with blood collection, analysis and plasma/serum processing.

Follow ChroMedX Corp.:
Facebook: facebook.com/ChroMedXcorp
Twitter: http://www.twitter.com/ChroMedXcorp

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

ChroMedx’s CEO, Wayne Maddever available for media interviews to discuss the HemoPalm, a new breakthrough in Point of Care Medical Testing

Toronto, ON -- (ReleaseWire) -- 09/23/2015 -- Each year, hundreds of thousands of patients come to the ER experiencing life threatening events such as possible carbon monoxide poisoning or heart attacks, attending doctors in a medical institution rely on the current standard blood gas analyzers to diagnose the oxygen-carrying capabilities of blood, blood gases and electrolytes. Normally, these type of tests are taken with an arterial blood sample (typically an artery in the arm), and are then sent off to a central lab, where a bench top unit uses spectroscopy and electrochemical sensor measurements to provide results. It can take hours to get the results.

But what if a lab in a hospital is not an option and time may be ticking for first responders at a scene of a fire or when a heart attack patient is being transported?

A new technology developed by Toronto-based ChroMedx called HemoPalm, is working to address this. The HemoPalm utilizes a small sample of blood via the finger, providing a result on the spot, with no specialist required. The technology is especially beneficial to first responders, such as paramedics, who can take the blood sample right at the scene and then transfer the data back to the hospital before the patient even arrives when time is crucial as in the case with fire victims as paramedics cannot tell how badly the patient has been poisoned by carbon monoxide. The information can then be transmitted back to the hospital before the patient is wheeled into the ER triage.

Aside from the first responders, the technology can be used for physicians at disaster relief such as Doctors without Borders, emerging economies or in the military where central laboratories may not exist or may be too far away.

In a hospital, the HemoPalm could simplifying sample collection and expediting patient results, both in the emergency department and the operating room, where the device could replace multiple machines currently in use. Another use would be for respiratory care, allowing respiratory therapists and visiting nurses to optimize treatment in the hospital and at home with comprehensive results of oxygen in the blood.

Wayne Maddever, Ph.D., P.Eng. Director, President & CEO, ChroMedx can discuss the following:

- What is point of care testing (POCT) and describe key differences between consumer testing and those implemented in the clinical setting

- How are blood gas analyzers testing currently performed, why the standard can be vastly improved? Why time is of the essence.

- What is HemoPalm and how does the technology work?

- What are the ideal settings for the HemoPalm? Where is it needed the most?

- How does the HemoPalm help patients around the world and empower doctors who do not have access to a lab?

- When can we expect to use this technology?

To book a media interview with Dr. Maddever or obtain video graphics of the HemoPalm, please contact: Janet Vasquez, JV Public Relations NY 212-645-6598 jvasquez@jvprny.com

Additional information for press:

About Wayne Maddever, Ph.D., P.Eng. Director, President & CEO, ChroMedx
Wayne Maddever received his B.A.Sc./M.A.Sc/Ph.D. in Metallurgical and Materials Science Engineering from the University of Toronto. He began his career with the Gas Products Division of Union Carbide (now Praxair) in both the US and Canada where he held positions in research and development, product management and sales management. He has considerable experience in the plastic moulding industry having headed a Division of St. Lawrence Starch, which developed and commercialized degradable plastics. He is familiar with precision equipment manufacture having served as General Manager of Sanden Machine, a printing press manufacturer and as COO of CFN Precision, a precision machining company producing parts for aircraft and scientific instruments. Dr. Maddever also operated Ontario's third largest home oxygen therapy and medical supply company as General Manager-Canada for MG Industries a German industrial gases company

About ChroMedX Corp.
ChroMedX Corp. is a medical technology company focused on the development of novel medical devices for in vitro diagnostics and point-of-care testing. The devices are protected by the Company's issued and pending patents, dealing with blood collection, analysis and plasma/serum processing.

Follow ChroMedX Corp.:
Facebook: http://www.facebook.com/ChroMedXcorp
Twitter: http://www.www.twitter.com/ChroMedXcorp

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

Toronto, ON -- (SBWIRE) -- 09/17/2015 -- ChroMedX Corp. (the "Company"), a developer of in vitro diagnostics and point-of-care testing (POCT) is pleased to announce that it has entered into a collaboration with Dr. Leyla Soleymani of the Biointerface Institute of McMaster University and received an Engage Grant from NSERC (Natural Sciences and Engineering Research Council of Canada) to further HemoPalmTM biosensor development.

Dr. Soleyemani's work will focus on novel biosensor technology which has the potential to both reduce the cost of the HemoPalmTM biosensors as well as broaden the scope of the types of analytes which can be measured.

The McMaster and ChroMedX partnership has been awarded an NSERC Engage Grant which is funded by NSERC (Natural Sciences and Engineering Research Council of Canada).

"We are pleased to be working with Dr. Soleymani on this project. Her novel approach to sensor technology holds great promise for us. In addition this relationship with the Biointerface Institute broadens and enhances an already significant relationship with McMaster University. We also thank NSERC for awarding this grant which will be of benefit to the development of Canadian medical technology"

Dr. Leyla Soleymani is an Associate Professor in the Department of Engineering Physics . Her specific area of research is the development of biosensors for Point-of-care applications. Her sensors feature high surface area which has the potential to enhance response and accuracy of the HemoPalmTM system.

"I am excited to be working with the ChroMedX team on their novel HemoPalmTM Point-of-care system" said Dr. Soleymani, Assistant Professor, Biointerfaces Institute, McMaster University

About ChroMedX Corp
ChroMedX Corp. is a medical technology company focused on the development of novel medical devices for in vitro diagnostics and point-of-care testing. The devices are protected by the Company's issued and pending patents, dealing with blood collection, analysis and plasma/serum processing.

Follow ChroMedX Corp.:
Facebook: http://www.facebook.com/ChroMedXcorp
Twitter: http://www.twitter.com/ChroMedXcorp

Investor Relations:
Shawn Overton
d. 647-528-9344
o. 647-872-9982 ext. 2
TF. 844-247-6633 ext. 2
soverton@ChroMedX.com

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

Toronto, ON -- (SBWIRE) -- 09/10/2015 -- ChroMedX Corp. (the "Company"), a developer of in vitro diagnostics and point-of-care technologies is pleased to report that testing has commenced on the key spectroscopic component of the Analyzer of HemoPalm(TM) blood analysis device.

The spectroscopic analysis of blood samples is a key aspect of the HemoPalm system which significantly differentiates it from other point-of-care blood analyzers and replicates the testing methods seen in central laboratory benchtop devices.

Through the previously announced collaborative project with Dr. Cynthia Balion at McMaster University, calibration algorithms for the various hemoglobin (Hb) species referred to as CO-oximetry, are being developed using blood samples collected for the "Canadian Longitudinal Study on Aging", in which Dr. Ballion is a key investigator. The microspectrometer used was supplied by Insion, Germany - the same microspectrometer that will be incorporated in the HemoPalm(TM) analyzer.

To date results for total hemoglobin(Total-Hb) and methhemoglobin (Met-Hb) have shown good correlation with FDA approved benchtop analyzer results. Testing and algorithm development continues for the other Hb species that will enable the HemoPalm(TM) to provide total CO-oximetry results. CO-oximetry measures the various hemolglobin (Hb ) species present in the blood and is a critical and unique aspect of the HemoPalm(TM) compared to other point-of-care blood analyzers in the market. As an example, one of the Hb species is used to detect carbon monoxide poisoning.

During the CO-oximetry investigation, a calibration algorithm was developed for measurement of bilirubin in whole blood. Bilirubin is an indicator of jaundice and has particular importance in the prediction and treatment of neonatal jaundice.

"The progress shown in these two areas moves us closer to completion of the alpha prototype of the HemoPalm(TM) Analyzer system. Demonstration of the ability to measure bilirubin from whole blood in a hand-held analyzer with no sample preparation is a significant development in POCT. This provides the foundation for a second cartridge in the HemoPalm(TM) line and a potential second analyte market" said Dr. Wayne Maddever, President & CEO, ChroMedX Corp.

The Company most recently announced the completion of the fabrication of the prototype HemoPalm(TM) cartridge, in conjunction with the McMaster Manufacturing Research Institute (MMRI). A complete archive of the Company's news can be found on the ChroMedX website.

About ChroMedX Corp.
ChroMedX Corp. is a medical technology company focused on the development of novel medical devices for in vitro diagnostics and point-of-care testing. The devices are protected by the Company's issued and pending patents, dealing with blood collection, analysis and plasma/serum processing.

Follow ChroMedX Corp.:
Website: http://www.ChroMedX.com
Facebook: facebook.com/ChroMedXcorp
Twitter: http://www.twitter.com/ChroMedXcorp

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

Toronto, ON -- (SBWIRE) -- 09/08/2015 -- ChroMedX Corp. (the "Company") (CSE: CHX, OTC: MNLIF, Frankfurt: EIY2), a developer of in vitro diagnostics and point-of-care testing (POCT) is pleased to report the completion of the HemoPalmTM System Prototype Cartridge.

In conjunction with the previously announced ENGAGE grant with McMaster University's Manufacturing Research Institute (MMRI), the Company has completed the fabrication of the prototype HemoPalmTM cartridge, a key component of the HemoPalmTM analysis system. MMRI produced the prototype by micromachining and testing of cartridge operation including calibration fluid pouch activation and microfluidic flow has already begun. Development of CO-oximetry calibration algorithms at McMaster University is underway.

Management is making available a photo of the see-through HemoPalmTM prototype cartridge identifying key components. The see through material allows easy observation of fluid flow during cartridge testing. The image can be pulled off this link:

https://static1.squarespace.com/static/52cad214e4b0d4d2bd05e2a4/t/55ea026ee4b0d610b736236d/1441399408107/?format=500w

"This is the first major step in the completion of the HemoPalmTM system alpha prototype. The cartridge is a critical element of the system and contains several novel features that set it apart from competitive products. Micromachining of the prototype cartridges has allowed rapid design modifications when needed, avoiding the time and cost of modifications to conventional plastic injection molds. Needless to say, we are very pleased with our collaboration with McMaster." said Dr. Wayne Maddever, President & CEO, ChroMedX Corp.

The Company is also pleased to present a 3D schematic video of the HemoPalmTM Analyzer system which demonstrates the sequence of operations commencing with the scanning of the cartridge for identification followed by spectroscopic CO-oximetry measurement, biosensor fluid calibration and biosensor measurement of blood gases and electrolytes. The video can be viewed by clicking this link: https://www.youtube.com/watch?v=PQ38FLtRTSk

ChroMedX recently announced the engagement of Polygenesis Corporation to complete the development of the biosensor technology aspect of the HemoPalmTM system as well as complete the development of the prototype analyzer.

About ChroMedX Corp.
ChroMedX Corp. is a medical technology company focused on the development of novel medical devices for in vitro diagnostics and point-of-care testing. The devices are protected by the Company's issued and pending patents, dealing with blood collection, analysis and plasma/serum processing.

Follow ChroMedX Corp.
Facebook: http://facebook.com/ChroMedXcorp
Twitter: http://www.twitter.com/ChroMedXcorp

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

Toronto, ON -- (SBWIRE) -- 09/03/2015 -- ChroMedX Corp, a developer of in vitro diagnostics and point-of-care testing (POCT) is pleased to announce the engagement of technology development and prototyping firm Polygenesis Corporation to continue the development of the HemoPalm™ biosensor array, a fundamental component of the HemoPalm™ system.

Polygenesis will build on the initial work carried out by Aline Inc. and complete the development of the biosensor array and associated electronics. In addition Polygenesis will be responsible for the development of the alpha prototype of the HemoPalm™ system.

Polygenesis Corporation is led by Henry Wieck Ph.D. Dr. Wieck had previously been a senior executive with POCT device manufacturer i-STAT during that company's early development and commercialization phase. Later i-STAT was acquired by Abbott.

"At i-STAT Dr. Wieck's expertise in electrochemistry was instrumental in the development of i-STAT's biosensor system. This world leading expertise is now being engaged in the development of ChroMedX's new biosensor technology", said Dr. Wayne Maddever, President & CEO, ChroMedX Corp.

"We are pleased to be involved with ChroMedX and its novel HemoPalm™ technology development. The combination of spectroscopic and biosensor measurement techniques promises to offer significant improvements over current POC devices. Polygenesis prides itself in its ability to tangibilize new products such as the HemoPalm™ as the first step in the commercialization process", said Dr. Henry Wieck, President of Polygenesis Corporation.

About Polygenesis Corporation
Polygenesis was founded in 1996 by Henry Wieck Ph.D. Since then Polygenesis has served many clients in areas ranging from Pharmaceuticals, Medical Devices, Transportation, Industrial and Commercial enterprises. The Company's headquarters are located in Central NJ near Princeton, and provide services for worldwide clients.

About ChroMedX Corp.
ChroMedX Corp. is a medical technology company focused on the development of novel medical devices for in vitro diagnostics and point-of-care testing. The devices are protected by the Company's issued and pending patents, dealing with blood collection, analysis and plasma/serum processing.

Follow ChroMedX Corp.:

Facebook: http://www.facebook.com/ChroMedXcorp
Twitter: http://www.twitter.com/ChroMedXcorp

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

Toronto, ON -- (SBWIRE) -- 09/01/2015 -- ChroMedX Corp(the "Company"), a developer of in vitro diagnostics and point-of-care testing (POCT) technologies is pleased to announce the filing of a PCT (Patent Cooperation Treaty) Patent Application pertaining to the HemoPalm(TM) Cartridge and Analyzer system called "Joint Spectroscopic and Biosensor System for Point-of-Care Testing" (PCT/CA2015/050455).

PCT/CA2015/050455 has the potential to effectively extend the lifespan of the Company's issued US Patent pertaining to the HemoPalm(TM) system, and to provide patent protection outside the US, in particular Europe, China and India. The application claims priority to U.S. Patent Application Nos. 62/114,700 and 62/006,066.

"We are continuing our efforts to expand the Company's Intellectual Property portfolio and are very pleased with the progress made to date", said Dr. Wayne Maddever, ChroMedX Corp., President & CEO.

The Company's HemoPalm(TM) and Ultrafiltration technologies are covered by several issued and pending patents. A list of issued and pending patents can be found on the company's website here: http://www.chromedx.com/intellectual-property/

Other Business

ChroMedX is pleased to announce the engagement of JV Public Relations New York to lead its PR efforts in the United States.

JV Public Relations New York (JVPRNY) is a full-service life science communications agency working to meet the needs of emerging and innovative life science companies. With a collective 30 years of experience, JVPRNY's founder, Janet Vasquez ran award-winning global and local public relations campaigns for an array of life science, pharmaceutical and biotechnology clients, while simultaneously managing highly successful programs for companies in laboratory, medical device, diagnostics/companion diagnostics industries. In addition, the JVPRNY team is well-versed in the social media landscape, having designed and implemented social media programs for several JVPRNY clients that span from non-profit consumer health to biotechnology firms.

JVPRNY's goal is to elevate ChroMedX Corp's profile in the US markets and engage proactive dialogues on the rising interest of point-of-care testing. JVPRNY's targeted media campaign includes traditional media interviews with print, broadcast and online publications outlets including expert opinion pieces targeting healthcare decision makers.

ChroMedX Corp. also welcomes Shawn Overton as Investor Relations Manager to the Company. Mr. Overton's primary responsibilities will be to manage shareholder correspondence and liaise with the financial community.

The Company recently announced a listing on the US OTC QB Exchange and the closing of a private placement for approximately CAD $1.1MM. ChroMedX announcements can be found here: http://www.chromedx.com/news/

For more information you can visit the ChroMedX Corp. website: http://www.ChroMedX.com

About ChroMedX Corp.
ChroMedX Corp. is a medical technology company focused on the development of novel medical devices for in vitro diagnostics and point-of-care testing. The devices are protected by the Company's issued and pending patents, dealing with blood collection, analysis and plasma/serum processing.

Follow ChroMedX Corp.:
Facebook: http://www.facebook.com/ChroMedXcorp
Twitter: http://www.twitter.com/ChroMedXcorp

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm